The Lynx Group
Cholangiocarcinoma News

Cholangiocarcinoma Research Continues to Thrive

December 2021, Vol 2, No 4
Milind M. Javle, MD
Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
Chair
NCI Task Force: Hepatobiliary Cancers

Dear Readers,

The Third CCA Summit was held on October 21-22, 2021 in New Orleans. For the majority of the cholangiocarcinoma (CCA) community, this was their first “live” meeting since the pandemic. The summit was attended live or virtually by a total of 165 participants, and was co-chaired by Ghassan K. Abou-Alfa, MD, MBA, and Rachna T. Shroff, MD, MS, and provided a valuable opportunity for clinicians and researchers in the field. In this last issue of 2021, we are highlighting key research presented at the summit, as well as in the recent peer-reviewed literature.

Jesús M. Bañales, PhD, discussed the role of epigenetics, posttranslational modifications, and metabolism in CCA and highlighted several targets for therapy, such as the epigenetic axis, the neddylation pathway, and metabolic targeting of fatty acid oxidation with specific inhibitors, which may indeed represent the next generation of inhibitors in CCA.

Nabeel El-Bardeesy, PhD, presented interesting findings from his laboratory regarding immunogenicity of IDH1-altered CCA, rendering these tumors susceptible to checkpoint inhibition.

Lewis Roberts, MBChB, PhD, described the fascinating association between genomic variations and environmental risk factors in a global study led by his team.

Clinical trials have thus far focused on systemic delivery of chemotherapy, whereas liver-directed approaches may be critical for liver-limited CCA, suggested Juan W. Valle, MBChB, MSc, and Skye C. Mayo, MD, MPH. The assessment of radiological response may be more sophisticated today, with enhanced radiomic technologies that may also be invaluable for prognostication.

James Costello, MD, PhD, and Laurent Dercle, MD, PhD, presented novel biomarker imaging data, which may be transformative in the clinic.

Richard Kim, MD, and Do-Youn Oh, MD, PhD, discussed the expanding role of immunotherapy with checkpoint inhibition in CCA, emphasizing that the CCA community eagerly awaits the results of the TOPAZ-1, S1815, and KEYNOTE-966 phase 3 clinical trials, which may change the treatment paradigm of this disease.

It remains to be seen if immunotherapy can benefit the majority of patients with CCA, and efforts to enhance efficacy by combining immunotherapeutic and targeted agents will be critical in this regard, according to Mark Yarchoan, MD.

Multimodality approaches that include surgery, perioperative therapy, and transplantation for liver-limited intrahepatic CCA may be curative in selected patients, suggested Alice C. Wang, MD, MSc, and Shimul A. Shah, MD, MHCM.

Several Keynote presentations and panels were also featured at the summit, including a global Keynote Panel that provided perspectives on CCA from the United States, the European Union, Latin America, and Asia. Dr Bañales highlighted the importance of implementing the new ICD-11 codes (which go into effect on January 1, 2022) to improve our understanding of CCA subtypes across the globe.

Stacie Lindsey, CEO, Cholangiocarcinoma Foundation (CCF), delivered a Keynote Address that highlighted the need for collaboration and the need to focus on the patient in drug development.

And a Keynote Roundtable discussion reviewed the drug pipeline for CCA, highlighting zanidatamab, a bispecific HER2 antibody, which was granted a breakthrough therapy designation by the FDA in November 2020 for patients with HER2-amplified biliary tract cancer.

Also in this issue, Reham Abdelwahab, Director of Research & Chief Scientific Officer of CCF reviews research initiatives sponsored by the foundation, detailing the specific ICD-11 codes, by indication, for immediate reference.

Finally, in this issue, we are highlighting 3 recent articles from the peer-reviewed literature. Together with Mitesh J. Borad, MD, and Nilofer S. Azad, MD, and colleagues, we investigated the use of trastuzumab plus pertuzumab in patients with biliary tract cancer and HER2/neu amplification, which showed a 23% response rate that was often long-lasting in a chemorefractory patient population.

Karthikeyan Murugesan, MS, and colleagues investigated the genomic underpinnings of hepatocellular CCA, pointing out the dimorphic pattern of genomic alterations in this composite disease. And Jianzhen Lin, PhD, and colleagues reviewed the evolution of gallbladder cancer from preneoplastic lesions and the pivotal role of CTNNB1 mutations in the development of this malignancy.

Clearly, CCA research continues to thrive, and we will learn more soon, at the ASCO GI Cancers Symposium in late January 2022!

Sincerely,

Milind Javle, MD

Milind M. Javle, MD
Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
Chair
NCI Task Force: Hepatobiliary Cancers

Related Items

Mechanisms of Resistance to FGFR Inhibitors
By Jesús Bañales, PhD; Antoine Hollebecque, MD; Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc
Videos
Drs Javle, Bañales, and Hollebecque discuss the innate and acquired resistance pathways to FGFR inhibitors in cholangiocarcinoma and how these pathways can have important effects on clinical outcomes. They also look ahead to ongoing clinical trials evaluating next-generation FGFR inhibitors that may be able to overcome resistance mechanisms and improve progression-free and overall survival in cholangiocarcinoma.
Molecular Profiling Should Now Be Routine Practice in Patients with CCA
By Milind M. Javle, MD
September/October 2021, Vol 2, No 3
This issue of CCA News features yet another exciting FDA approval for cholangiocarcinoma (CCA), ivosidenib, which was recently approved for CCA with IDH1 mutation. This is the third drug approved for CCA in the past 2 years, highlighting the critical role of molecular profiling in this cancer. Up to 20% of patients with intrahepatic CCA have IDH1 mutation, and the ClarIDHy phase 3 study demonstrated improvement in progression-free survival with ivosidenib versus placebo for chemorefractory disease. The FDA also approved the Oncomine Dx Target Test for IDH1 mutations.
Evolution in Biomarker Testing in CCA
By Jesús Bañales, PhD; Antoine Hollebecque, MD; Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc
Videos
Using next-generation sequencing to detect FGFR fusion partners and co-mutations to improve efficacy in treating CCA
Incorporating FGFR Inhibitors into the Treatment Paradigm for Cholangiocarcinoma: Current Concepts and Future Directions
By Mitesh J. Borad, MD; Milind M. Javle, MD; Michael Morse, MD, FACP, MHS; Lewis R. Roberts, MB, ChB, PhD
June/July 2021, Vol 2, No 2
On January 15, 2021, experts in the management of patients with cholangiocarcinoma (CCA) convened for a virtual accredited continuing education satellite symposium held during the 2021 annual meeting of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The goal was to educate healthcare providers on various aspects of CCA, including epidemiology, current standards of care, unmet clinical needs, the safety and efficacy of fibroblast growth factor receptor (FGFR) inhibitors as second-line therapy, and practical approaches to incorporating FGFR inhibitors into the treatment paradigm for the disease.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: